局部外用肾上腺素能血管收缩剂显著抑制乳腺癌患者放射性皮炎
本项IIa期研究在保乳术后接受全乳放疗(至少40 Gy)的乳腺癌患者中,于每次放疗前20分钟在照射野内固定50 cm²区域局部外用NG12-1血管收缩剂。结果显示,NG12-1治疗区放射性皮炎平均评分0.47(SD 0.24),显著低于同一照射野内对照区的0.72(SD 0.22),P=0.022;9例可评分患者均观察到皮炎减轻,未见严重不良事件。
要点
- 放疗前20分钟局部外用NG12-1可显著降低放射性皮炎评分。
- 9例可评分患者均观察到皮炎减轻,未发生严重不良事件。
核心结论
- 每日放疗前局部外用NG12-1血管收缩剂可统计学显著降低保乳术后乳腺癌患者放射性皮炎严重程度,P=0.022。
研究设计与样本
- IIa期研究,纳入保乳术后接受全乳放疗至少40 Gy的Ia、Ib或IIa期浸润性导管/小叶癌或导管原位癌患者。
- NG12-1于每次每日放疗分次前20分钟局部外用于照射野内同一50 cm²治疗区域。
主要发现
- NG12-1治疗区平均皮炎评分为0.47(SD 0.24),对照区为0.72(SD 0.22),P=0.022。
- 两名独立研究者分析显示,9例可评分皮炎严重程度的患者中9例皮炎均减轻。
- 另有1例患者皮炎程度不足以评分。
- NG12-1治疗未出现严重不良事件。
关键数值与推荐
- 主要疗效指标为同一照射野内NG12-1治疗区与对照区的皮炎评分比较,P=0.022。
临床怎么用
- 对于接受全乳放疗至少40 Gy的保乳术后乳腺癌患者,可考虑在每次放疗前20分钟于照射野内局部外用NG12-1以减轻放射性皮炎。
局限性
- 原文未报告研究局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Our previous studies showed that vasoconstrictor applied topically to rat skin minutes before irradiation completely prevented radiodermatitis. Here we report on a Phase IIa study of topically applied NG12-1 vasoconstrictor to prevent radiodermatitis in post-lumpectomy breast cancer patients who received at least 40 Gray to the whole breast using standard regimens. METHODS: Patients had undergone surgery for Stage Ia, Ib, or IIa infiltrating ductal or lobular carcinoma of the breast or ductal carcinoma in situ. NG12-1 formulation was applied topically to the same 50-cm2 treatment site within the radiation field 20 min before each daily radiotherapy fraction. RESULTS: Scores indicated significant reductions in radiodermatitis at the NG12-1 treatment site versus control areas in the same radiotherapy field. The mean dermatitis score for all subjects was 0.47 (SD 0.24) in the NG12-1-treated area versus 0.72 (SD 0.22) in the control area (P = 0.022). Analysis by two independent investigators indicated radiodermatitis reductions in 9 of the 9 patients with scorable radiodermatitis severity, and one patient with insufficient radiodermatitis to enable scoring. There were no serious adverse events from NG12-1 treatment. CONCLUSIONS: Thirty, daily, NG12-1 treatments, topically applied minutes before radiotherapy, were well tolerated and conferred statistically significant reductions in radiodermatitis severity (P = 0.022). TRIAL REGISTRATION: NCT01263366 ; clinicaltrials.gov.
引用
- Cleary JF, Anderson BM, Eickhoff JC, et al. Significant suppression of radiation dermatitis in breast cancer patients using a topically applied adrenergic vasoconstrictor. Radiat Oncol. 2017. PMID: 29273054. doi:10.1186/s13014-017-0940-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。